$MGTA News
Last published 3y ago
- 3y agoMGTAMagenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock SplitGlobeNewswireCAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's
- 3y agoHSKAMGTARUTHSYNHMoore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law FirmGlobeNewswireNEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoMGTAMagenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementGlobeNewswireMerger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180
- 3y agoMGTAMagenta Therapeutics Adopts Limited Duration Stockholder Rights PlanGlobeNewswireCAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited
- 3y agoMGTAMagenta Therapeutics to Explore Strategic AlternativesGlobeNewswireCAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it has completed a
- 3y agoMGTAMagenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug SafetyGlobeNewswireCAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2
- 3y agoMGTAMagenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program UpdatesGlobeNewswire– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients
- 3y agoMGTAMagenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical TrialGlobeNewswireCAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to
- 4y agoMGTAMagenta Therapeutics Reports Third Quarter Financial Results and Recent Program HighlightsGlobeNewswire– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has
- 4y agoMGTAMagenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual MeetingGlobeNewswire– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism – – Poster presentation of data from a MGTA-117 non-human primate study that
- 4y agoMGTAMagenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to
- 4y agoMGTAMagenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced tha
- 4y agoMGTAMagenta Therapeutics Reports Second Quarter Financial Results and Recent Program HighlightsGlobeNewswire– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability profile; interim clinical data disclosure anticipated i
- 4y agoMGTAMagenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced tha
- 4y agoMGTAMagenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program HighlightsBusiness Wire– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a favorable tolerability profile – – IND-en
- 4y agoMGTAMagenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash RunwayBusiness Wire– Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial – – Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 – Magenta Therapeutics (NASDAQ:MGTA), a clinical-sta
- 4y agoMGTAMagenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program HighlightsBusiness Wire– First patient dosed in MGTA-117 targeted conditioning Phase 1/2 clinical trial; clinical data is expected in 2022 – – IND-enabling preclinical studies initiated for CD45 antibody-drug conjugate; dose-ranging toxicology results expected in the
- 4y agoMGTAMagenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare ConferenceBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a Cell Therapy Pan
- 4y agoMGTAOPKSMFRSMFRWSema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data PlatformGlobeNewswireBusiness combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland,
- 4y agoMGTAMagenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022Business Wire-- MGTA-117 Phase 1/2 clinical trial is open for enrollment for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes; clinical data expected in 2022 –- -- CD45 antibody drug conjugate is Magenta's second conditio
- 4y agoMGTAMagenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology ConferenceBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following Janu
- 4y agoMGTAMagenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual MeetingBusiness Wire-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple myeloma -- -- Phase 2 development of MGTA-145 to
- 5y agoMGTAMagenta Therapeutics Reports Third Quarter Financial Results and Program HighlightsBusiness Wire-- Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor in patients with multiple myeloma will be presented as a
- 5y agoMGTAMagenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual MeetingBusiness Wire-- Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma -- -- Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle
- 5y agoMGTAMagenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical TrialBusiness Wire– Phase 1/2 clinical trial expected to open in Q4 2021 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) – Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company deve
- 5y agoMGTAMagenta Therapeutics Reports Second Quarter Financial Results and Recent Program HighlightsBusiness Wire– Progress in addressing the FDA's recommendations regarding bioassay and dose escalations to clear the current clinical hold on the company's Investigational New Drug Application to initiate MGTA-117 Phase 1/2 clinical trial – – Enrollment c
- 5y agoMGTAMagenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in AugustBusiness WireMagenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August
- 5y agoCMLFMGTATWSTSema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform CompanyGlobeNewswireSema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic mode
- 5y agoMGTAMagenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeBusiness WireMagenta Therapeutics, Inc. (NASDAQ:MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 cl
- 5y agoCMLFMGTANVTAOMIC+2Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of DirectorsBusiness WireSema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's B
- 5y agoMGTAMagenta Therapeutics Appoints Caren Deardorf as Chief Commercial OfficerBusiness WireMagenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first C
- 5y agoMGTAMagenta Therapeutics Appoints Thomas Beetham as Chief Legal OfficerBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer. "We
- 5y agoMGTAMagenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire– Preliminary results from the initial cohort of 10 patients were previously reported on May 12 in a published abstract at the European Hematology Association (EHA) Congress – – The cumulative data as of the data cut-off date show that all pati
- 5y agoMGTAMagenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare ConferenceBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat
- 5y agoMGTAMagenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in MayBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Offic
- 5y agoMGTAMagenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117Business Wire- Preliminary results showed all patients with multiple myeloma (10/10) treated with MGTA-145 and plerixafor met the primary endpoint for stem cell mobilization and collection, and all transplanted patients (6/6) successfully engrafted as of the data cu
- 5y agoMGTAMagenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple InvestorsBusiness WireMagenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its
- 5y agoMGTAMagenta Therapeutics Reports First Quarter Financial Results and Recent Program HighlightsBusiness Wire– Two Phase 2 clinical trials underway to evaluate MGTA-145 plus plerixafor; initial mobilization, collection, engraftment and disease outcome data in Multiple Myeloma patients to be first presented at the American Society of Clinical Oncology (ASCO)
- 5y agoMGTAMagenta Therapeutics Appoints David Nichols as Chief Technical OfficerBusiness WireMagenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of David Nichols as Chief Technical Officer.
- 5y agoMGTAMagenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines ...
- 5y agoMGTAMagenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 202 ...
- 5y agoMGTAMagenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Thursday, March 18th, 2021, at 10:00 a.m. ET.
- 5y agoMGTAMagenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program HighlightsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2020 and recent program highlights.
- 5y agoMGTAMagenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Ann ...
- 5y agoMGTATLMDAnne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit CommitteeBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thornton’s Global Health Care and Life Sciences Practices, has joined its Board of Directors and chair of the Audit Committee.
- 5y agoMGTAKLDOMagenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical TrialsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates ...
- 5y agoMGTAMagenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 14th, 2021, at 10:50 a.m. ET, immediately foll ...
- 5y agoMGTAMagenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed Phase 1 clinical trial as well as development updates for its MGTA-145 stem cell mobilization therapy, including commencement ...
- 5y agoMGTABLUEMagenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell DiseaseBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-con ...
- 6y agoMGTAMagenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating OfficerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.